Form SC14D9C - Written communication relating to third party tender offer

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14D-9

Solicitation/Recommendation Statement

Under Section 14(d)(4) of the Securities Exchange Act of 1934

 

 

ICOSAVAX, INC.

(Name of Subject Company)

 

 

ICOSAVAX, INC.

(Name of Person Filing Statement)

 

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

45114M109

(CUSIP Number of Class of Securities)

Adam Simpson

Chief Executive Officer

Icosavax, Inc.

1930 Boren Avenue, Suite 1000

Seattle, Washington 98101

[phone]

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications

on Behalf of the Person Filing Statement)

With copies to:

 

Cheston J. Larson Matthew T. Bush Latham & Watkins LLP 12670 High Bluff Drive San Diego, CA 92130 [phone]		Elizabeth Bekiroğlu General Counsel Icosavax, Inc. 1930 Boren Avenue, Suite 1000 Seattle, Washington 98101 [phone]

 

 

 

☒	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 

---

The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Icosavax, Inc. on December 12, 2023 (including all exhibits attached thereto and incorporated therein by reference) is incorporated herein by reference.

---